Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 3, 2006, Pages 31-41

  File Jr , T M ^a,b  

^a SUMMA HEALTH SYSTEM   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Implication; Multiresistant; Pneumonia; Review; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIUM ISOLATION; CANADA; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DRUG CHOICE; DRUG EFFICACY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IN VITRO STUDY; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 33645817952     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01395.x     Document Type: Review

References (57)

1. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis. JAMA 1996; 275: 134-141.
2. File TM Jr. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
3. File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: Focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34 (Suppl. 1): S17-S26.
4. Felmingham D. Comparative antimicrobial susceptibility of respiratory pathogens. Chemotherapy 2004; 50 (Suppl. 1): 3-10.
5. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: An overview. Clin Infect Dis 1992; 15: 77-83.
6. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994-95: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-1213.
7. Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumonaie in the United States: Have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 139-148.
8. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN and the Alexander Project Group. The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
9. Nishijima T, Saito Y, Aoki A. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibiity to various antibiotcs. J Antimicrob Chemother 1999; 43: 637-643.
10. Ho PI, Yung RWH, Tsang DNC et al. Increasing resistance of Streptococcus pneumoinae to fluoroquinolones: Results of a Hong Knog multicenter study in 2000. J Antimciob Chemther 2001; 48: 659-665.
11. McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international muliresistant clones. J Antimicrob Chemother 2002; 49: 173-176.
12. Chen DK, McGeer A, de Azavedo JC, Low DE for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
13. Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study. Clin Infect Dis 2001; 32: 701-701.
14. File TM Jr. Telithromycin new product overview. J Allergy Clin Immunol 2005; 115: S1-S13.
15. Schmitz FJ, Schwarz S, Milatovic D et al. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 2001; 45: 2427-2431.
16. Farrell DJ, Jenkins SG, Brown SD et al. Emergence and spread of Streptococcus pneumoniae with erm and mef resistance. Emerg Infect Dis 2005; 11: 851-858.
17. Baquero F, Martínez-Beltrán J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991; 28 (Suppl. C): 31-38.
18. Hyde TB, Gay K, Stephens DS et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857-1862.
19. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of β-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-370.
20. Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: Duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36: 1132-1138.
21. Yu VL, Chiou CCC, Feldman C et al. for the International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-237.
22. Richter SS, Heilmann KP, Coffman SL et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 2002; 34: 330-339.
23. Einarsson S, Kristjansson M, Kristinsson KG et al. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study. Scand J Infect Dis 1998; 30: 253-256.
24. Plouffe JF, Breiman RF, Facklam RR for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention. JAMA 1996; 275: 194-198.
25. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-97. Am J Public Health 2000; 90: 223-229.
26. Battleman D, Oppenheim M, Zuccotti G et al. Clinical and economic consequences of bacterial resistance in community-acquired pneumococcal pneumonia. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25, 2001. Chicago, Illinois: American Society for Microbiology, 2001; O-393
27. Pallares R, Liñares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
28. Metlay JP, Hofmann J, Cetron MS et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-528.
29. Turret GS, Blum S, Fazal BA et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29: 321-327.
30. Moroney JF, Fiore AE, Harrison LH et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33: 797-805.
31. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002; 2: 404-415.
32. Klugman KP, Feldman C. Streptococcus pneumoniae respiratory tract infections. Curr Opin Inf Dis 2001; 14: 173-179.
33. Metlay JP. Update on community-acquired pneumonia: Impact of antibiotic resistance on clinical outcomes. Curr Opin Inf Dis 2002; 15: 163-167.
34. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to β-lactam antibiotics. Arch Intern Med 2001; 161: 2538-2544.
35. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococcal in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31: 613-615.
36. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-1011.
37. Musher DM, Dowell ME, Shortridge VD et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346 (8): 630-631.
38. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-559.
39. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 2002; 49: 433-436.
40. Anderson KB, Tan JS, File TM Jr et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376-381.
41. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-750.
42. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia [Letter]. N Engl J Med 2002; 347: 65-66.
43. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infection: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
44. Low D. Changing trends in antimicrobial-resistant pneumococci: It's not all bad news. Clin Infect Dis Supplement 2005; 4: 41: S22-S232.
45. Bruinsma N, Kristinsson KG, Bronzaaer S et al. Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. J Antimicrob Chemother 2004; 54: 1045-1050.
46. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17 (3): 479-501.
47. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65: 949-991.
48. File TM Jr, Jacobs MR, Michael D et al. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/ clavulanate. Int J Antimicrob Agents 2002; 20: 235.
49. Low DE, Felmingham D, Brown SD, Rangaraju M, Nusrat R. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. Journal of Infection 2004; 49: 115-25.
50. File TM Jr, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-1901.
51. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433
52. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730-1754.
53. Mandell LA, Marrie TJ, Grossman RE et al. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
54. File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Inf Dis Clinics North Am 2004; 18: 993-1016.
55. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl. IV): iv1-iv64.
56. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
57. Dagan R, Sikuler-Cohen M, Zamir O et al. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care centre attendees. Pediatr Infect Dis J 2001; 20: 951-958.